Literature DB >> 2329264

Determination of IGF-II levels in human serum using the erythroleukemia cell line K562.

G L Spadoni1, M Tally, K Florell, G Enberg, K Hall.   

Abstract

A homologous radioreceptor assay (RRA) has been developed for Insulin-like Growth Factor II (IGF II) using the human erythroleukemia cell line K562. These cells have binding sites for insulin and IGF-II but not for Insulin-like Growth Factor I (IGF I). All samples were dissociated and separated from binding proteins by gel filtration at acidic pH. In healthy adults the mean serum level of radioreceptor assayable IGF II (RRA-IGF II) and 95% confidence limits were 965 ng/ml and 717-1299 ng/ml, respectively. The mean level in GH deficient patients was significantly lower (p less than 0.001) compared with healthy subjects whereas no change was found in patients with acromegaly and uremia. Slightly lowered levels of RRA-IGF II were found in one patient with a tumor induced hypoglycemia.

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2329264     DOI： 10.1007/BF03349516

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN： 0391-4097            Impact factor:   4.256


  23 in total

1.  Serum somatomedin A in chronic renal failure.

Authors:  K Takano; K Hall; K W Kastrup; N Hizuka; K Shizume; K Kawai; M Akimoto; T Takuma; N Sugino
Journal:  J Clin Endocrinol Metab       Date:  1979-03       Impact factor: 5.958

2.  Lack of a simple relationship between endogenous growth hormone and NSILA-s related peptides.

Authors:  K Megyesi; P Gorden; R Kahn
Journal:  J Clin Endocrinol Metab       Date:  1977-08       Impact factor: 5.958

3.  Somatomedin and growth after renal transplantation.

Authors:  P Saenger; E Wiedemann; E Schwartz; S Korth-Schutz; J E Lewy; R R Riggio; A L Rubin; K H Stenzel; M I New
Journal:  Pediatr Res       Date:  1974-03       Impact factor: 3.756

4.  Uremia reduces serum insulin-like growth factor I, increases insulin-like growth factor II, and modifies their serum protein binding.

Authors:  A C Goldberg; B Trivedi; J A Delmez; H R Harter; W H Daughaday
Journal:  J Clin Endocrinol Metab       Date:  1982-12       Impact factor: 5.958

5.  Inhibition of access of bound somatomedin to membrane receptor and immunobinding sites: a comparison of radioreceptor and radioimmunoassay of somatomedin in native and acid-ethanol-extracted serum.

Authors:  W H Daughaday; I K Mariz; S L Blethen
Journal:  J Clin Endocrinol Metab       Date:  1980-10       Impact factor: 5.958

6.  Synthesis and secretion of insulin-like growth factor II by a leiomyosarcoma with associated hypoglycemia.

Authors:  W H Daughaday; M A Emanuele; M H Brooks; A L Barbato; M Kapadia; P Rotwein
Journal:  N Engl J Med       Date:  1988-12-01       Impact factor: 91.245

7.  Is extrapancreatic tumor hypoglycemia associated with elevated levels of insulin-like growth factor II?

Authors:  U Widmer; J Zapf; E R Froesch
Journal:  J Clin Endocrinol Metab       Date:  1982-11       Impact factor: 5.958

8.  Somatomedin in growth disorders and chronic renal insufficiency in children.

Authors:  S L Schwalbe; P R Betts; P H Rayner; B T Rudd
Journal:  Br Med J       Date:  1977-03-12

9.  Radioimmunological determination of insulinlike growth factors I and II in normal subjects and in patients with growth disorders and extrapancreatic tumor hypoglycemia.

Authors:  J Zapf; H Walter; E R Froesch
Journal:  J Clin Invest       Date:  1981-11       Impact factor: 14.808

Review 10.  Serum somatomedin binding proteins: physiologic significance and interference in radioligand assay.

Authors:  W H Daughaday; M Kapadia; I Mariz
Journal:  J Lab Clin Med       Date:  1987-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.